×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Therapeutic: TGR5 Agonist Therapy
therapeutic
1,441 words
KG: TGR5
Contents
TGR5 Agonist Therapy
💊
Therapeutic Info
Name
TGR5
Key Genes/Proteins
NFE2L2
,
NRF2
,
STAT3
Related Diseases
Alzheimer's disease
,
Motor Dysfunction
,
Parkinson's Disease
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.71
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.92
CYP46A1 Overexpression Gene Therapy
Score: 0.92
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.85
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Microglial Purinergic Reprogramming
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Ganglioside Rebalancing Therapy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.68
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.67
Complement C1q Subtype Switching
Score: 0.66
Show 25 more
Related Analyses (27)
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 22 more
Related Experiments (7)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Acteoside treatment in LPS-induced SALI mouse model
validation · proposed · Score: 0.90
Resveratrol protection against renal I/R injury in diabetic
validation · proposed · Score: 0.90
Nrf2 inhibitor ML385 mechanism validation experiment
exploratory · proposed · Score: 0.85
Resveratrol effects on HK-2 cells under hypoxia/reoxygenatio
exploratory · proposed · Score: 0.85
Acteoside effects on RAW264.7 macrophage cells
exploratory · proposed · Score: 0.85
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Show 2 more
See Also (15)
NeuRon Therapeutics
company · KG edge: expressed_in
NRF2 Gene
gene · KG edge: activates
NFE2L2 — Nuclear Factor Erythroid 2-Related Factor 2
gene · KG edge: activates
STAT3 (Redirect)
redirect · KG edge: activates
NRF2 Activator Therapy
idea · KG edge: activates
Neuroprotection Strategies in Neurodegeneration
therapeutic · KG edge: mediates
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 5 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 5 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 4 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-
clinical · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
nct05508789
clinical_trial · Pages share 3 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 3 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (12 edges)
GPS
activates
TGR5
TGR5
activates
NRF2
DCA
activates
TGR5
TGR5
activates
STAT3
TGR5
expressed_in
neuron
Gentiopicroside
targets
TGR5
TGR5
activates
NFE2L2
Gentiopicroside
activates
TGR5
TGR5
involved_in
Parkinson's Disease
TGR5
associated_with
Alzheimer's disease
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)